1、Risk of Developing Alzheimers Disease in Persons with MCI,Survival curve of persons characterized as having a mild cognitive impairment for 6 years. Approximately 80% have converted to dementia during this time.,Peterson RC, et al., Arch Neurol. 58:1985-1992, 2001.,Normal, 75 years old,Alzheimers di
2、sease, 75 years old,Volume of Hippocampus and Rate of Shrinkage Predicts Crossover from MCI to AD,Jack CR, et al, Neurology 55: 484-489, 2000,De Leon MJ, 1999,PET Imaging of Amyloid Deposits in Alzheimers Disease vs Normal Controls,Source: Klunk, et al. Ann Neurol 2004: 55:306-319.,PET imaging with
3、a novel tracer, Pittsburgh Compound-B (PIB), can provide quantitative information on amyloid deposits in living subjects.,Current Drug Treatments for AD,Acetylcholinesterase inhibitors for mild to moderate AD Tacrine (Cognex) Denepezil (Aricept) Rivastigmine (Exelon) Galantamine (Reminyl) Neuroprote
4、ctive agent for moderate to severe AD Memantine (Namenda),Funded AD Prevention and Selected Treatment Trials,April 2002,Complementary & Alternative Therapies for AD,Ginkgo Evaluation of Memory (GEM) study Clinical trial of huperzine Traditional Asian medicines High intensity light therapy,REACH II Intervention,The REACH II intervention is a multi-component intervention designed to address five areas linked to caregiver risk profile: Safety Social Support CR Problem Behaviors Emotional well-being Self-care and Health Behaviors,
